pyrrolidonecarboxylic acid has been researched along with daunorubicin in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ansorge, P; Csík, G; Fellinger, E; Kulić, Z; Manea, M; Mezo, G; Möller, HM; Orbán, E; Schlage, P | 1 |
| Geršl, V; Hašková, P; Jirkovský, E; Mertlíková-Kaiserová, H; Popelová, O; Simůnek, T; Stěrba, M; Vávrová, A | 1 |
| Baranyai, Z; Kapuvári, B; Leurs, U; Manea, M; Marquardt, A; Mezo, G; Öhlschläger, P; Orbán, E; Schulcz, Á; Tejeda, M; Tóvári, J | 1 |
| Kapuvári, B; Manea, M; Mezo, G; Schulcz, A; Tejeda, M; Tóvári, J; Vincze, B | 1 |
| Kőhidai, L; Lajkó, E; Leurs, U; Manea, M; Marquardt, A; Mező, G; Öhlschläger, P; Orbán, E | 1 |
| Halmos, G; Hegedüs, R; Kiss, E; Manea, M; Mező, G; Orbán, E; Sipos, E; Szabó, I | 1 |
| Dürr, C; Manea, M; Marquardt, A; Mező, G; Orbán, E; Schreier, VN | 1 |
| Limonta, P; Manea, M; Marzagalli, M; Montagnani Marelli, M; Moretti, RM | 1 |
| Gacs, A; Hegedüs, R; Kapuvári, B; Manea, M; Mező, G; Schulcz, Á; Tóvári, J; Vincze, B | 1 |
| Fossati, G; Kapuvári, B; Mező, G; Ranđelović, I; Schuster, S; Steinkühler, C; Tóvári, J | 1 |
| Gennari, C; Halmos, G; Juhász, É; Mező, G; Neundorf, I; Schuster, S | 1 |
11 other study(ies) available for pyrrolidonecarboxylic acid and daunorubicin
| Article | Year |
|---|---|
In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites.
Topics: Amino Acid Sequence; Animals; Antibiotics, Antineoplastic; Cathepsin B; Cell Line, Tumor; Cell Survival; Daunorubicin; DNA; Fluorescence; Gonadotropin-Releasing Hormone; Humans; Liver; Lysosomes; Molecular Structure; Oximes; Peptide Fragments; Pyrrolidonecarboxylic Acid; Rats; Serum | 2011 |
In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Buthionine Sulfoximine; Cell Line; Daunorubicin; Dose-Response Relationship, Drug; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Heart; Heart Diseases; Hydrogen Peroxide; Male; Models, Animal; Oxidative Stress; Pyrrolidonecarboxylic Acid; Rabbits; Rats; Thiazolidines | 2011 |
Enhanced enzymatic stability and antitumor activity of daunorubicin-GnRH-III bioconjugates modified in position 4.
Topics: Amino Acid Sequence; Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Daunorubicin; Drug Stability; Female; Gonadotropin-Releasing Hormone; Humans; Lysosomes; Mice; Mice, Inbred BALB C; Neoplasms; Protein Structure, Secondary; Pyrrolidonecarboxylic Acid; Rats; Serum | 2011 |
In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Daunorubicin; Dose-Response Relationship, Drug; Female; Gonadotropin-Releasing Hormone; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Mice, SCID; Pyrrolidonecarboxylic Acid; Xenograft Model Antitumor Assays | 2012 |
GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Cell Adhesion; Cell Proliferation; Daunorubicin; Drug Carriers; Drug Stability; Gonadotropin-Releasing Hormone; Humans; Liver; Lysosomes; Methotrexate; Peptide Fragments; Pyrrolidonecarboxylic Acid; Rats | 2012 |
Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates.
Topics: Acylation; Antineoplastic Agents; Cell Proliferation; Circular Dichroism; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fatty Acids; Gonadotropin-Releasing Hormone; HT29 Cells; Humans; MCF-7 Cells; Molecular Structure; Pyrrolidonecarboxylic Acid; Receptors, LHRH; Structure-Activity Relationship | 2012 |
Synthesis, enzymatic stability and in vitro cytostatic effect of Daunorubicin-GnRH-III derivative dimers.
Topics: Animals; Cell Proliferation; Cytostatic Agents; Daunorubicin; Dimerization; Dose-Response Relationship, Drug; Enzyme Stability; Gonadotropin-Releasing Hormone; Humans; MCF-7 Cells; Pyrrolidonecarboxylic Acid; Rats; Structure-Activity Relationship | 2013 |
Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Daunorubicin; Dose-Response Relationship, Drug; Gonadotropin-Releasing Hormone; Humans; Male; Oximes; Prostatic Neoplasms, Castration-Resistant; Pyrrolidonecarboxylic Acid; Receptors, LHRH; Tumor Cells, Cultured | 2015 |
Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice.
Topics: Animals; Antibiotics, Antineoplastic; Butyric Acid; Cell Proliferation; Colorectal Neoplasms; Daunorubicin; Female; Gonadotropin-Releasing Hormone; Heart; HT29 Cells; Humans; Liver; Male; Mice; Neovascularization, Pathologic; Pyrrolidonecarboxylic Acid; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Daunorubicin; Disease Models, Animal; Female; Gene Expression; Gonadotropin-Releasing Hormone; Humans; Male; Mice; Molecular Structure; Pyrrolidonecarboxylic Acid; Receptors, Cell Surface; RNA, Messenger; Toxicity Tests; Xenograft Model Antitumor Assays | 2019 |
Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cathepsin B; Cell Line, Tumor; Daunorubicin; Female; Gonadotropin-Releasing Hormone; Humans; Molecular Targeted Therapy; Ovarian Neoplasms; Paclitaxel; Petromyzon; Pyrrolidonecarboxylic Acid; Receptors, LHRH | 2022 |